Literature DB >> 11158744

Carbapenem resistance mechanisms in Pseudomonas aeruginosa clinical isolates.

H Pai1, J Kim, J Kim, J H Lee, K W Choe, N Gotoh.   

Abstract

In order to define the contributions of the mechanisms for carbapenem resistance in clinical strains of Pseudomonas aeruginosa, we investigated the presence of OprD, the expressions of the MexAB-OprM and MexEF-OprN systems, and the production of the beta-lactamases for 44 clinical strains. All of the carbapenem-resistant isolates showed the loss of or decreased levels of OprD. Three strains overexpressed the MexAB-OprM efflux system by carrying mutations in mexR. These three strains had the amino acid substitution in MexR protein, Arg (CGG) --> Gln (CAG), at the position of amino acid 70. None of the isolates, however, expressed the MexEF-OprN efflux system. For the characterization of beta-lactamases, at least 13 isolates were the depressed mutants, and 12 strains produced secondary beta-lactamases. Based on the above resistance mechanisms, the MICs of carbapenem for the isolates were analyzed. The MICs of carbapenem were mostly determined by the expression of OprD. The MICs of meropenem were two- to four-fold increased for the isolates which overexpressed MexAB-OprM in the background of OprD loss. However, the elevated MICs of meropenem for some individual isolates could not be explained. These findings suggested that other resistance mechanisms would play a role in meropenem resistance in clinical isolates of P. aeruginosa.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11158744      PMCID: PMC90316          DOI: 10.1128/AAC.45.2.480-484.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  29 in total

1.  Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of Pseudomonas aeruginosa.

Authors:  T Köhler; M Michéa-Hamzehpour; U Henze; N Gotoh; L K Curty; J C Pechère
Journal:  Mol Microbiol       Date:  1997-01       Impact factor: 3.501

2.  Expression of the multidrug resistance operon mexA-mexB-oprM in Pseudomonas aeruginosa: mexR encodes a regulator of operon expression.

Authors:  K Poole; K Tetro; Q Zhao; S Neshat; D E Heinrichs; N Bianco
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

3.  Differential selection of multidrug efflux systems by quinolones in Pseudomonas aeruginosa.

Authors:  T Köhler; M Michea-Hamzehpour; P Plesiat; A L Kahr; J C Pechere
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

Review 4.  Are all beta-lactams created equal?

Authors:  D M Livermore
Journal:  Scand J Infect Dis Suppl       Date:  1996

5.  Meropenem permeation through the outer membrane of Pseudomonas aeruginosa can involve pathways other than the OprD porin channel.

Authors:  F J Pérez; C Gimeno; D Navarro; J García-de-Lomas
Journal:  Chemotherapy       Date:  1996 May-Jun       Impact factor: 2.544

6.  Protein D2 porin of the Pseudomonas aeruginosa outer membrane bears the protease activity.

Authors:  E Yoshihara; N Gotoh; T Nishino; T Nakae
Journal:  FEBS Lett       Date:  1996-09-30       Impact factor: 4.124

7.  Characterization of beta-lactamase gene blaPER-2, which encodes an extended-spectrum class A beta-lactamase.

Authors:  A Bauernfeind; I Stemplinger; R Jungwirth; P Mangold; S Amann; E Akalin; O Anğ; C Bal; J M Casellas
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

8.  Characterization of the MexC-MexD-OprJ multidrug efflux system in DeltamexA-mexB-oprM mutants of Pseudomonas aeruginosa.

Authors:  N Gotoh; H Tsujimoto; M Tsuda; K Okamoto; A Nomura; T Wada; M Nakahashi; T Nishino
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

9.  Role of mexA-mexB-oprM in antibiotic efflux in Pseudomonas aeruginosa.

Authors:  X Z Li; H Nikaido; K Poole
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

10.  OXA-14, another extended-spectrum variant of OXA-10 (PSE-2) beta-lactamase from Pseudomonas aeruginosa.

Authors:  F Danel; L M Hall; D Gur; D M Livermore
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

View more
  59 in total

1.  Clinical strains of Pseudomonas aeruginosa overproducing MexAB-OprM and MexXY efflux pumps simultaneously.

Authors:  Catherine Llanes; Didier Hocquet; Christelle Vogne; Dounia Benali-Baitich; Catherine Neuwirth; Patrick Plésiat
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

2.  Phage therapy to control multidrug-resistant Pseudomonas aeruginosa skin infections: in vitro and ex vivo experiments.

Authors:  A Vieira; Y J Silva; A Cunha; N C M Gomes; H-W Ackermann; A Almeida
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-07-10       Impact factor: 3.267

3.  Characterization of In100, a new integron carrying a metallo-{beta}-lactamase and a carbenicillinase, from Pseudomonas aeruginosa.

Authors:  Sandra Quinteira; João Carlos Sousa; Luísa Peixe
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

4.  Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model.

Authors:  Phillip J Bergen; Jürgen B Bulitta; Carl M J Kirkpatrick; Kate E Rogers; Megan J McGregor; Steven C Wallis; David L Paterson; Roger L Nation; Jeffrey Lipman; Jason A Roberts; Cornelia B Landersdorfer
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

5.  Differential effects of levofloxacin and ciprofloxacin on the risk for isolation of quinolone-resistant Pseudomonas aeruginosa.

Authors:  Keith S Kaye; Zeina A Kanafani; Ashley E Dodds; John J Engemann; Stephen G Weber; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

6.  Characterization of Hypermutator Pseudomonas aeruginosa Isolates from Patients with Cystic Fibrosis in Australia.

Authors:  Vanessa E Rees; Deanna S Deveson Lucas; Carla López-Causapé; Yuling Huang; Tom Kotsimbos; Jürgen B Bulitta; Murray C Rees; Adele Barugahare; Anton Y Peleg; Roger L Nation; Antonio Oliver; John D Boyce; Cornelia B Landersdorfer
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

Review 7.  What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles.

Authors:  Karen Bush; Malcolm G P Page
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-02-04       Impact factor: 2.745

8.  Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.

Authors:  Carolina Alvarez-Ortega; Irith Wiegand; Jorge Olivares; Robert E W Hancock; José Luis Martínez
Journal:  Antimicrob Agents Chemother       Date:  2010-08-02       Impact factor: 5.191

9.  Resistance mechanisms of multiresistant Pseudomonas aeruginosa strains from Germany and correlation with hypermutation.

Authors:  B Henrichfreise; I Wiegand; W Pfister; B Wiedemann
Journal:  Antimicrob Agents Chemother       Date:  2007-09-17       Impact factor: 5.191

10.  Nosocomial acquisition of Pseudomonas aeruginosa resistant to both ciprofloxacin and imipenem: a risk factor and laboratory analysis.

Authors:  M R Mueller; M K Hayden; S K Fridkin; D K Warren; L Phillips; K Lolans; J P Quinn
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-02-26       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.